Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma - PubMed (original) (raw)
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma
Terence C Chua et al. Liver Int. 2010 Feb.
Abstract
Resection of hepatocellular carcinoma (HCC) offers the only hope for cure. However, in patients undergoing resection, recurrences, in particular, intrahepatic recurrence are common. The effectiveness of transarterial chemoembolization (TACE) as a neoadjuvant therapy for unresectable HCC was exploited by numerous liver units and employed preoperatively in the setting of resectable HCC with an aim to prevent recurrence and prolong survival. A systematic literature search of databases (Medline and PubMed) to identify published studies of TACE administered preoperatively as a neoadjuvant treatment for resectable HCC was undertaken. A systematic review by tabulation of the results was performed with disease-free survival (DFS) as the primary endpoint. Overall survival (OS), rate of pathological response, impact on surgical morbidity and mortality and pattern of recurrences were secondary endpoints of this review. Eighteen studies; three randomized trials and 15 observational studies were evaluated. This comprised of 3927 patients, of which, 1293 underwent neoadjuvant TACE. The median DFS in the TACE and non-TACE group ranged from 10 to 46 and 8 to 52 months, respectively, with 67% of studies reporting similar DFS between groups despite higher extent of tumour necrosis from the resected specimens indicating a higher rate of pathological response (partial TACE 27-72% vs. non-TACE 23-52%; complete TACE 0-28% vs. non-TACE zero), with no difference in surgical morbidity and mortality outcome. No conclusion could be drawn with respect to OS. Both randomized and non-randomized trials suggest the use of TACE preoperatively as a neoadjuvant treatment in resectable HCC is a safe and efficacious procedure with high rates of pathological responses. However, it does not appear to improve DFS.
Similar articles
- Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.
Kan XF, Liang B, Zhang XL, Yu L, Luo YC, Zhou S, Liu RB, Xu GH, Li HL, Liao ZY, Xiang H, Lu W, Xu LF, Ma YL, Xia XW, Qian K, Dong XJ, Xiong F, Song SL, Zhao C, Huang M, Zheng CS. Kan XF, et al. BMC Med. 2025 May 28;23(1):313. doi: 10.1186/s12916-025-04159-y. BMC Med. 2025. PMID: 40437469 Free PMC article. Clinical Trial. - Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Lobo L, et al. Cardiovasc Intervent Radiol. 2016 Nov;39(11):1580-1588. doi: 10.1007/s00270-016-1426-y. Epub 2016 Sep 1. Cardiovasc Intervent Radiol. 2016. PMID: 27586657 - Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L. Li L, et al. BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0. BMC Gastroenterol. 2018. PMID: 30180810 Free PMC article. - Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
Fan W, Zhu B, Chen S, Wu Y, Zhao X, Qiao L, Huang Z, Tang R, Chen J, Lau WY, Chen M, Li J, Kuang M, Peng Z. Fan W, et al. JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831. JAMA Oncol. 2024. PMID: 38900435 Free PMC article. Clinical Trial.
Cited by
- Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis.
Hu R, Xu J, Wang H, Wang J, Lei K, Zhao X, Zhang H, You K, Liu Z. Hu R, et al. BMC Cancer. 2024 Feb 9;24(1):190. doi: 10.1186/s12885-024-11978-4. BMC Cancer. 2024. PMID: 38336712 Free PMC article. - Current status of multimodal & combination therapy for hepatocellular carcinoma.
Yang J, Yan L, Wang W. Yang J, et al. Indian J Med Res. 2012 Sep;136(3):391-403. Indian J Med Res. 2012. PMID: 23041732 Free PMC article. Review. - Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Fu Y, Zhao X, Yun Q, Zhu X, Zhu Y, Li Q, Hu K, Wang J, Qiao Z. Fu Y, et al. Int J Clin Exp Med. 2015 Jul 15;8(7):10388-400. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26379829 Free PMC article. - Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.
Gao ZH, Bai DS, Jiang GQ, Jin SJ. Gao ZH, et al. World J Hepatol. 2015 Jan 27;7(1):40-3. doi: 10.4254/wjh.v7.i1.40. World J Hepatol. 2015. PMID: 25624995 Free PMC article. Review. - Neutrophil-to-lymphocyte ratio as an index of treatment response to trans-arterial chemoembolization in hepatocellular carcinoma.
Shayegan N, Ayoobi N, Mohammadi E, Saberi H, Salahshour F, Alborzi F, Ziamanesh F, Sadighi N, Taher M. Shayegan N, et al. Gastroenterol Hepatol Bed Bench. 2024;17(3):253-259. doi: 10.22037/ghfbb.v17i3.2925. Gastroenterol Hepatol Bed Bench. 2024. PMID: 39308535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous